Skip to main content
. Author manuscript; available in PMC: 2013 Dec 22.
Published in final edited form as: Mol Pharm. 2012 Jun 22;9(8):2280–2289. doi: 10.1021/mp300152v

Figure 6.

Figure 6

In vivo oncogenes silencing inhibits NSCLC tumor growth. (a) Tumor growth curve of H460 subcutaneous model. (b) Tumor growth curve of A549 subcutaneous model. (c) Dose response curve on A549 subcutaneous model. ED50=205 μg/kg. Data = mean ± SD, n = 5. *, p < 0.05; **, p < 0.01 comparing to the 5% GS group. H460 tumors were treated every 3 day starting at day 7 for 5 times and A549 tumors was treated every 5 days starting at day 11 for 6 times.